1212-The Cartography of KRAS Inhibitor Resistance

This paper discusses how colorectal cancer develops resistance to KRAS G12C inhibitors through complex genomic and transcriptomic shifts. Researchers found that tumors undergo epithelial cell plasticity, moving from a regenerative state to a Paneth or stem-like phenotype during treatment. This adaptation includes the emergence of pro-inflammatory pathways that persist even as the disease progresses and eventually reverts to its original fetal-like state. Spatial analysis reveals that these resistant environments are highly localized within a single tumor, involving both cancer cells and the surrounding stroma. Ultimately, the text suggests that targeting these inflammatory nodes could be a viable strategy for improving therapeutic outcomes. This research emphasizes the need for multifaceted diagnostic approaches to better monitor the evolving nature of drug resistance in patients.References:White M, Campbell AD, Sansom OJ. The cartography of KRAS inhibitor resistance in colorectal cancer. Cancer Cell. 2026 Jun 11:S1535-6108(26)00255-2. doi: 10.1016/j.ccell.2026.05.010. Epub ahead of print. PMID: 42276046.前往小宇宙评论区与主播互动